Airway infections initiated by the interaction of bacterial adhesins with carbohydrate receptors can be potentially prevented by nontoxic carbohydrate inhibitors. Intranasal inoculation of neonatal mice with Pseudomonas aeruginosa PAO1 caused pneumonia in 55% of control mice but in only 13% of mice inoculated 2 h after dextran inhalation ( ) and P ! .001 in 28% inoculated 4 h after dextran inhalation ( ). PAO1 adherence to epithelial cells P ϭ .02 was inhibited by 50% in the presence of dextran. Dextran was well distributed throughout the airways and stimulated tumor necrosis factor-a production in murine lungs but not interleukin-8 production by human epithelial cell lines. Phagocytosis of PAO1 was not affected by dextran nor was killing by human neutrophils diminished. Administration of dextran by aerosol may prevent murine pneumonia by impeding bacterial access to epithelial receptors and by stimulation of the immune functions of the epithelium.
Many human pathogens recognize the carbohydrate moieties of epithelial glycoconjugates as receptors to initiate colonization and infection. The use of carbohydrates to block bacterial recognition of glycoconjugate receptors and prevent infection has been considered and used in several biologic systems [1] . Cranberry juice, which contains a saccharide effective in preventing the attachment of piliated Escherichia coli to uroepithelial glycolipid receptors, is a well-known example. Oligosaccharides are currently being tested to inhibit the attachment of Helicobacter pylori to epithelial glycolipids to prevent gastric ulcer disease [2] . Bacteria commonly associated with pneumonia also bind to carbohydrate receptors on the pulmonary epithelium [3] , providing the theoretical basis for using inhaled carbohydrates to prevent infection. The increasing use of many therapeutic agents, such as inhaled DNase and aminoglycoside antibiotics, particularly in patients with cystic fibrosis (CF) suggests that this therapeutic modality can be safe and effective.
Much of the pathology associated with CF airway disease is thought to be due to an exceptionally vigorous immune response elicited in part by bacteria within the airway lumen [4] . Pseudomonas aeruginosa that evade normal mucociliary clearance and the lytic activity of antimicrobial peptides [5, 6] bind to asialylated receptors on the epithelial surface via pilin [7] and flagellin adhesins [8] . Such asialylated receptors are relatively few in normal hosts but are more numerous on the epithelial cells of persons with mutations in the CF transmembrane conductance regulator [9] . Bacterial adherence to these receptors activates the translocation of nuclear factor kB and results in the epithelial expression of interleukin (IL)-8, a major neutrophil chemokine that initiates the polymorphonuclear leukocyte (PMNL)-dominated inflammation typical of this disease [10] . Activated PMNLs releasing reactive oxygen intermediates and neutrophil elastase further damage the epithelium and perpetuate the cycle of inflammation. In the normal host, damage to the epithelium induced by nosocomial trauma or viral infection and subsequent epithelial regeneration also result in the exposure of asialylated glycolipids and similarly predispose to P. aeruginosa adherence [11] and the ensuing inflammatory response. Blocking bacterial activation of the epithelial cytokine response, even partially, might decrease the pathologic consequences of excessive airway inflammation.
There has been great interest in developing therapeutic agents to prevent the acquisition of opportunistic pathogens, such as P. aeruginosa in CF and nosocomial pneumonias in intubated patients with compromised airway defense mechanisms. Dextran, a polymer of a(1,6) linked D-glucose (branched at the 3 position) is a widely available polysaccharide that has been safely used in clinical settings as a plasma expander [12] . In vitro studies suggest that dextran is effective in blocking the adherence of P. aeruginosa, Haemophilus influenzae, Staphylococcus aureus, and group A streptococcus to A549 pulmonary epithelial cells [13] . Dextran was also shown in an in vitro assay to improve the rheologic properties of sputum from CF patients, presumably by reducing the cross-link density and cohesiveness [14] . In this study, we examined the effects of inhaled dextran in a neonatal mouse model of P. aeruginosa pneumonia.
Our purpose was to determine if dextran, which blocks bacterial adherence to epithelial monolayers in vitro, can protect the airways in an intact animal from colonization and to characterize the nature and severity of the immunologic reaction to dextran administered to the murine lung.
Methods
Bacterial strains and culture conditions. The P. aeruginosa strains used are listed in table 1. The mutated strains were constructed by gene replacement using a cloned copy of the wild-type gene in which the coding sequence is interrupted by a gentamicin or a tetracycline cassette. PAK/NPfliC contains a mutation-blocking expression of the flagellin structural gene and an interrupted pilin structural gene. The constructions were confirmed by Southern hybridization, and the phenotypes were documented by loss of motility and resistance to pilus-dependent phages where appropriate. Organisms were grown with aeration at 37ЊC in M9 media supplemented with glutamine as necessary. PAO1/pLS10 ( ) was constructed by cloning a 720-bp BamHIpUCP18 ϩ GFP HindIII DNA fragment encoding the green fluorescent protein (GFP) gene from Aequorea victoria into the polylinker of pUCP18 [15] .
Cell culture. Primary cultures of respiratory epithelial cells derived from nasal polyp tissue were grown to confluence in monolayers [16] . 1HAEoϪ cells, SV40 immortalized human airway epithelial cells for which epithelial properties have been well characterized [17] , were grown in 96-well plates in Dulbecco's MEM (DMEM)/F12 10% fetal calf serum (FCS; Sigma, St. Louis), and serum was starved for 18 h before stimulation for IL-8 assays.
Bacterial adherence assays. The number of P. aeruginosa adhering to the epithelial monolayers was quantified using 35 S-labeled organisms, as previously described [16] . The P. aeruginosa strains were grown to late log phase (2-cfu/mL) in minimal M9 5 ϫ 10 galactan, N-acetylglucosamine, dextran sulfate, malto-oligosaccharide, mannan, maltose, melibiose, raffinose, and trehalose (40 or 60 mg/mL; Sigma) or dextran (Polydex, Scarborough, Canada). The dextran was nominally 4000 molecular weight (MW) and was found by high-performance liquid chromatography to contain a range of polymer sizes and molecular species (up to 4000). After a 60-min incubation with the bacteria, the monolayers were rinsed 3 times with PBS, solubilized in 2% SDS, and associated organisms were quantified by counting scintillations. Each point was determined in quadruplicate and a mean and SD were determined. Differences in bacterial binding were analyzed for statistical significance by a two-tailed Student's t test (Excel software; Microsoft, Redmond, WA).
Fluorescein isothiocyanate (FITC)-dextran was made by reacting 4000-MW dextran with FITC (Sigma) using the method of DeBelder and Granath [18] . The product was purified by chromatography on Sephadex G-10.
Flow cytometry-cholera toxin binding. The number of epithelial cells with accessible GM1 residues, the receptor for the B subunit of cholera toxin [19] , was determined by flow cytometry. FITClabeled cholera toxin B subunit (List Biologicals, Campbell, CA) was incubated with epithelial mono mM dextran for layers ‫ע‬ 10 15 min, washed twice in PBS, lifted from the plates with 0.02% EGTA in 20 mM HEPES in PBS, and fixed in 1% paraformaldehyde. The cells were analyzed in a FACScan III (Becton Dickinson, San Jose, CA) for FITC fluorescence.
FITC-dextran binding. 1HAEoϪ cells were incubated at either 4 or 37ЊC with increasing concentrations of FITC-dextran (0-25 mg/mL) with or without unlabeled dextran (125 mg/mL) as a competitive inhibitor. After two washes in PBS, the monolayers were removed from the plates and analyzed by FACScan.
Macrophage ingestion studies. RAW 264.7 cells (murine macrophages) were grown at 37ЊC in 5% CO 2 in RPMI 1640 ϩ and 10% FCS in 24-well tissue culture plates and used glutamine 24-48 h after passage. Monolayers were inoculated with PAO1/ pLS10 (expressing GFP) or with PAO1/pUCp18 (controls) or were preincubated for 20 min with 60 mg/mL dextran. Bacteria (10 8 cfu/ mL in 0.5 mL) and monolayers were incubated at 37ЊC in 5% CO 2 for 1 h to allow ingestion to take place and then put on ice. Unattached bacteria were removed by three PBS washes. The RAW cells were taken up from the tissue culture wells by treatment with EGTA, fixed with 0.8% paraformaldehyde, and analyzed by flow cytometry by laser FACS III.
Neutrophil killing assay. Neutrophils (PMNL) were isolated from blood of laboratory workers by standard techniques and killing quantified as previously described [20] . The concentration of PMNL was adjusted to /mL in polypropylene tubes. An 6 5 ϫ 10 overnight culture of P. aeruginosa PAO1 was diluted to 6 5 ϫ 10 cfu/mL. In a total volume of 500 mL, we combined 50 mL of pooled human serum as an opsonin, 50 mL of bacteria, 250 mL of PMNL, and 100 mL of Hanks' balanced salt solution with 0.1% gelatin, glucose (50 mM), or dextran (50 mM), which was placed on a rotator at 37ЊC. Aliquots (50 mL) were removed at 0, 30, and 120 Downloaded from https://academic.oup.com/jid/article-abstract/179/6/1449/964075 by guest on 13 March 2019 Figure 1 . Infection in mice inoculated with PAO1 after inhalation of 10 mM dextran or mannan. PBS inoculation 2 h control ϭ PAO1 after PBS aerosol, dextran, or mannan 2 inoculation 2 h h ϭ PAO1 after dextran or mannan aerosol, respectively; dextran 4 h ϭ PAO1 inoculation 4 h after dextran aerosol. n ϭ no. of mice in each group. Bars show % of mice inoculated with Pseudomonas aeruginosa PAO1 that developed pneumonia, bacteremia (positive splenic culture), or died. min and diluted with distilled H 2 O, 1:100 for 10 min to lyse the PMNL. Further dilutions were done to enable bacterial colony counts, which were expressed as the log of the colony-forming units per milliliter. Assays were repeated on 3 different days, and the changes in the log of the bacterial growth were averaged and SDs calculated.
Mouse infection studies. BALB/c ByJ mice, age 9-11 days, mean weight g, were placed in a closed plastic chamber 7.2 ‫ע‬ 0.47 ( cm) and exposed to an aerosol of dextran (40 25.4 ϫ 20.3 ϫ 10.2 mg/mL) or mannan (20 mg/mL) in PBS or PBS alone for 15 min delivered by nebulizer (Thermocare model 16000; Caire, Littleton, CO). This nebulizer delivers 1 mL of 1-to 3-mm particles in 10-15 min. At 2 or 4 h after exposure to PBS, dextran, or mannan, the mice were intranasally inoculated with a 1-cfu of P. aeru- 8 3 ϫ 10 ginosa in 10 mL as previously described [7] . Mice were sacrificed 24 h later by use of Avertin (2,2,2 tribromoethanol; Aldrich, Milwaukee). The left lung and the spleen were homogenized in 100 mL of PBS and cultured. The right lung was fixed in formalin for routine histopathologic studies. Some lungs were immediately fixed in HistoPrep (Fisher Scientific, Fair Lawn, NJ) embedding compound (Miles, Elkhart, IN) and frozen at Ϫ70ЊC for immunocytochemical or immunofluorescence studies.
Pneumonia was defined as the recovery of 110 2 cfu of P. aeruginosa from a single minced lung, confirmed by histopathology, reviewed by a veterinary pathologist, indicative of: an acute bacterial pneumonia with gram-negative rods, PMNL infiltration, consolidation from fibrin deposition, and hemorrhage into bronchi and alveoli; these are criteria previously established for this model of infection [7] . Bacteremia was defined as recovery of any organisms from the spleen. Differences in the rates of pneumonia, bacteremia, and mortality between the control group and the groups given dextran or mannan followed by PAO were individually analyzed by Z test of proportions (Microsoft Excel).
Immunocytochemistry. Lungs were fixed in HistoPrep (Fisher) embedding compound, frozen in liquid N 2 , and cryosectioned onto poly L lysine-coated slides. Tumor necrosis factor (TNF)-a was detected using polyclonal rabbit anti-mouse TNF-a (Genzyme, Cambridge, MA) followed by biotinylated secondary antibody detection (Vectastain Elite ABC immunoperoxidase kit; Vector Laboratories, Burlingame, CA).
IL-8 assays. IL-8 in the epithelial cell culture supernatant was measured by ELISA using plates coated with monoclonal antibody to IL-8 (R&D Systems, Minneapolis) [16] . The epithelial cells in 96-well plates were stimulated with 200 mL of PAO1 ( cfu/ 7 5 ϫ 10 mL) with or without 10 mM dextran. Control wells received media only or 10 mM dextran in media. After 1 h, the monolayers were washed and placed in DMEM/F12 media with 100 mg/mL gentamicin. After 18 h, the supernatant was removed and assayed by ELISA. IL-8 was detected with rabbit polycolonal antibody (Genzyme). The integrity of the monolayer before the IL-8 assay was assessed by visualization, and cell viability after stimulation was confirmed by trypan blue exclusion. Each data point was determined at least in duplicate, and each experiment was done at least three times. Representative results from one experiment are shown. Differences in the amount of IL-8 produced by the cells under the conditions specified were compared by analysis of variance (Excel 5.0 software; Microsoft).
Results

Dextran prevents P. aeruginosa infection in neonatal mice.
Neonatal BALB/c ByJ mice are susceptible to an acute P. aeruginosa pneumonia and provide an opportunity to assess the events associated with the initial stages of infection in an immunologically intact animal. Individual litters of neonatal mice were exposed to an aerosol of 40 mg/mL dextran and then challenged 2 or 4 h later with an intranasal inoculation of P. aeruginosa PAO1. The resultant pulmonary disease was compared with that induced in identical litters of infected control animals pretreated with a PBS aerosol (figure 1). Twenty-four hours after inoculation, 55% of PBS-exposed mice challenged 2 h later with PAO1 had severe pneumonia, which was demonstrated histologically with infiltration of the airways by PMNL and changes typical of lobar pneumonia and by the recovery of 110 2 cfu/lung. Mortality was 20%. At 24 h after inoculation, 13% of the mice pretreated with dextran and exposed to PAO1 2 h later had 110 2 cfu recovered from the lung, demonstrating a highly protective effect (
). There was P ! .001 8% bacteremia ( ) and 4% (1/23) mortality ( ). P ! .001 P ϭ .06 More pathology was evident in mice exposed to PAO1 4 h after aerosolized dextran: 28% developed pneumonia ( ), 24% P ϭ .02 were bacteremic ( ), and 9.6% (2/21) died ( ), but P ϭ .03 P ϭ .14 significant protection remained. Mannan, a polymannose isolated from Saccharomyces cerevisiae cell wall at a concentration of 20 mg/mL was equally effective in protecting mice from P. aeruginosa infection up to 2 h after aerosol administration.
Typical sections of lung from controls and mice infected with PAO1, stained with anti-TNF-a (which appears as black de- by itself in the lung was also examined. Although the dextrantreated control animals appeared to be healthy, hematoxylineosin (HE)-stained lung sections had increased airway edema compared with control lungs (data not shown). Lung sections had a reticular pattern of TNF-a staining, but the large and small airways remained quite clear ( figure 2C ). This TNF-a pattern differed from that in the infected lung ( figure 2A ). Sections of the lung from animals pretreated with dextran, followed by PAO1 inoculation (figure 2D), looked much more like the normal control lung: The airways were generally clear, but there was increased edema and TNF-a staining was markedly decreased from that in infected lungs that were not pretreated (compare figure 2A and 2D) . The basic architecture of the lung was well preserved. The failure to culture significant numbers of organisms from the lungs of dextran-treated animals suggests that the local host defense mechanisms were sufficient to clear bacteria that reached the lower respiratory tract.
The histology of the pneumonia induced by PAO1 is better illustrated in the HE-stained sections of dextran-treated animals infected 4 h after aerosol ( figure 2E ). PAO1 caused a typical pneumonia in some of these mice, as shown with PMNL infiltration of all bronchioles, areas of fibrin deposition, and general consolidation with complete loss of the alveolar structures apparent in controls.
Dextran binds to proximal and distal airways in neonatal mice. The distribution of aerosolized dextran in neonatal mouse airways was determined by exposing mice to an aerosol of FITC-labeled dextran (particle size 1-3 mm) for 15-20 min. Thirty minutes after aerosol, there was evidence of FITC-dextran throughout the mouse lung, including the distal bronchioles and the more proximal trachea and larger bronchi. In addition to the expected superficial distribution of FITC-dextran, there appeared to be epithelial uptake, and intracytoplasmic fluorescence was apparent even at the earliest time points studied. The same pattern of FITC-dextran distribution in the lung remained 3.5 h after the aerosol was administered (figure 3) but was not seen in untreated controls.
Dextran blocks P. aeruginosa-induced IL-8 production.
To further determine how dextran affects the inflammatory response to P. aeruginosa, epithelial IL-8 production in vitro was measured following stimulation by PAO1 of human airway epithelial cells (1HAEoϪ) with or without 10 mM dextran. The endogenous IL-8 production by the 1HAEoϪ cells was minimal and was further reduced when the cells were incubated with dextran, indicating that dextran alone does not elicit IL-8 production in this system. In the presence of 10 mM dextran, epithelial production of IL-8 as stimulated by P. aeruginosa was completely blocked ( ) ( figure 4 ). P! .001 Dextran inhibition of PAO1 binding to epithelial cells. The amount of dextran required to inhibit bacterial binding was quantified by incubating cfu/mL 35 S-labeled P. aerugi-7 8 ϫ 10 nosa PAO1 with 1HAEoϪ cells in the presence of increasing amounts of dextran (figure 5). The effect of dextran in blocking PAO1 adherence was linear up to a concentration of 55 mg/ mL, and 190% inhibition of adherence was achieved at a concentration of 120 mg/mL. To verify that the data obtained with these transformed human airway cells was applicable to primary cells, binding assays were performed using nasal polyp cells in primary culture. In this experiment, of 23.3% ‫ע‬ 1.3% the PAO1 inoculum was adherent in the presence of PBS, compared with of the inoculum added to nasal polyp 15.3% ‫ע‬ 1.5% cells preincubated with 60 mg/mL dextran ( ) (data not P ϭ .001 shown).
The affinity of dextran for the epithelial cell surface was assessed by quantifying the binding of FITC-labeled dextran to 1HAEoϪ cells at 4 and 37ЊC (figure 6). At 37ЊC, the presence of unlabeled competitor (125 mg/mL) did not inhibit the binding of FITC-dextran. At 4ЊC, binding was saturated at dextran concentrations between 5 and 10 mg/mL. The failure to saturate at 37ЊC suggests that dextran is taken up by epithelial cells. This possibility is supported by the distribution of the inhaled FITC-dextran evident in the sections of mouse lung in which there is not only a bright ring of fluorescence lining the airways, as would be expected if the FITC-dextran remained superficial, but also fluorescence within the cell cytoplasm ( figure 3) .
Several additional saccharides of known structure were tested for the ability to block P. aeruginosa PAO1 binding to 1HAEoϪ epithelial cells ( figure 7) . Arabinogalactan from the Western larch, a 37,000 MW highly branched polysaccharide consisting of a 3,6-galactosopyranose backbone with 6-linked galactosyl and 3-linked arabinosyl side chains, was as effective as dextran in blocking PAO1 adherence to 1HAEoϪ cells. N-acetylglucosamine (221 MW), a common component of the epithelial cell surface, was also an effective inhibitor of P. aeruginosa binding, decreasing 50% of binding at 1 mg/mL (data not shown). Dextran sulfate (500,000 MW), a charged compound, was only slightly less active than dextran. Neither malto-oligosaccharide, a 1,4 D-glucose (4000-10,000 MW), nor mannan, an a1-4 polymer of D-mannose with a1-2 and a1-3 branches (34,000-62,000 MW), blocked PAO1 binding. Melibiose and raffinose contain glucose molecules linked at the 6 position to adjacent galactose. Their failure to block adherence suggests that a 6 linkage is not sufficient to interfere with Pseudomonas binding. Trehalose, a glucose disaccharide with an a1,1 linkage, also failed to block bacterial binding. We conclude from the range of sugar sizes that were able to block adherence that this inhibition does not depend solely on size or molarity of the solution.
Dextran is a large polymer that may act as a nonspecific physical barrier to different types of ligands. We tested the effect of dextran in blocking the binding of the B subunit of cholera toxin, a pentamer with a molecular mass of 59 kDa (slightly larger than P. aeruginosa flagellin), to its receptor, the common epithelial membrane component GM1. Epithelial cells preincubated with 10 mM dextran were treated with FITC-cholera toxin B subunit, and binding was quantified by flow cytometry. About 75% of the epithelial cell population were FITC-labeled under control conditions, compared with 58% in the presence of dextran, suggesting that dextran presents a relative but not an absolute barrier to molecules with affinity for epithelial membrane structures.
Dextran interactions with P. aeruginosa. Pilin-dependent binding accounts for ∼50% of P. aeruginosa attachment to epithelial cells, while a less well-characterized group of "nonpilus" adhesins, including flagellar proteins, also participate in binding [21] . The effect of dextran on the binding of P. aeruginosa mutants constructed by gene replacement with altered expression of either individual pilin or flagellar-associated adhesins was examined ( figure 8) . Adherence of the wild-type strain was significantly greater than adherence of any of the mutants (P ! ), and for each strain adherence in the presence of dextran .03 was significantly less than under control conditions ( ). P ! .004 In the presence of dextran, ∼48% of the binding of both the wild-type motile piliated strain PAK and the nonpiliated strain PAK/NP was inhibited by dextran, compared with 60% inhibition of the flagellar (fliC) mutant and 69% inhibition of the pilA/fliC mutant.
To further explore the interactions of P. aeruginosa and dextran, bacterial adherence assays were done by preincubating the organisms with dextran prior to adding them to the epithelial monolayers. Under these conditions, there was no blocking activity. We assessed the affinity of P. aeruginosa for dextran by incubating PAO1 with FITC-dextran and then examined the organisms by flow cytometry. Although the organisms could be brightly labeled with the fluorescent dextran, binding was not saturable, and the FITC-dextran could not be competed off the bacteria by unlabeled dextran (data not shown). Similarly, the addition of dextran to monolayers previously incubated with P. aeruginosa did not result in the displacement of any bound organisms. When the growth rate and viability of P. aeruginosa PAO1 in the presence of several concentrations of dextran were measured by following both optical density and associated colony-forming units at all points of the growth curve, they were unaffected by the polysaccharide under these conditions (data not shown). The lack of any significant affinity of dextran for either pilin or flagellin and its nonspecific effects in inhibiting binding in the absence of the major P. aeruginosa adhesins suggest that dextran blocks bacterial adherence by interacting primarily with host components.
Dextran and macrophage/monocyte ingestion of P. aeruginosa. An important component of immune clearance of inhaled pathogens is the activity of alveolar macrophages in the phagocytosis of these organisms. Dextran, which is readily taken up by macrophages, could alter the normal ingestion of these organisms either by acting as an opsonin and increasing clearance or by competing with P. aeruginosa for macrophage uptake. To determine how dextran affects macrophage interactions with P. aeruginosa in vitro, the ability of RAW cells (a murine monocyte/macrophage cell line) to interact with GFPlabeled PAO1 was tested with and without added dextran. Macrophages with ingested (or adherent) fluorescent organisms were quantified by flow cytometry. Under control conditions, 58% of the macrophages had associated bacteria over the course of the experiment versus 49% of the macrophages that had been preincubated with dextran prior to the addition of PAO1 (data not shown). Preincubation of the bacteria with dextran had no significant effect on the number of monocytic cells with associated organisms (61%). There were no apparent differences in the numbers of bacteria per cell assessed using these methods. Dextran and PMNL killing. The PMNL killing assays used human neutrophils to determine the effect of dextran on the ability of PMNL to kill the ingested organisms. Under the conditions of the assay system, PAO1 growth increased by 0.5 log over the 2-h course of the experiment in the absence of PMNL and human serum ( figure 9 ). In the presence of PMNL, , or , the number of organ-PMNL ϩ dextran PMNL ϩ glucose isms recovered was decreased by ∼1 log. There was no significant difference in the levels of killing obtained by PMNL alone or in the presence of dextran.
Discussion
The administration of dextran by aerosol was remarkably effective in preventing P. aeruginosa pneumonia in neonatal mice, reducing the infection rate by 43%. Analysis of the likely mechanisms through which this protection was afforded indicates that the involvement of dextran is more complicated than a simple competitive inhibition of an adhesin-receptor interaction. Several saccharides blocked bacterial adherence, and there was no apparent correlation between saccharide structure or branching pattern and the ability to block P. aeruginosa binding. The unrelated sugars arabinogalactan and N-acetylglucosamine were as effective as dextran in impeding PAO1 binding to human epithelial cells. Moreover, mannan, which did not inhibit P. aeruginosa attachment to epithelial cells in vitro, provided as much protection as dextran in preventing pneumonia in the mouse. Dextran had no specific effect in blocking pilin-dependent adherence. There was no evidence that dextran competed for binding to the asialoGM1 epithelial receptor. At best a 50% decrease in P. aeruginosa adherence could be demonstrated in the presence of dextran at the concentrations delivered to the murine airways, an effect that did not seem sufficient to account for the level of protection seen in the neonatal mice. Accordingly, we looked for additional effects that dextran might exert on the host immune clearance mechanisms.
Several experiments demonstrated important interactions between respiratory epithelial cells and dextran. Not only was there brisk and substantial uptake of the compound by cells throughout the murine airways and in tissue culture conditions, but there was also substantial activation of TNF-a expression by dextran-exposed epithelial cells. Dextran augments uptake of foreign DNA as demonstrated in gene therapy trials using adenovirus vectors and pulmonary epithelial cells [22] , and unmethylated bacterial DNA is an effective immunostimulant [23] . Although dextran by itself did not elicit epithelial IL-8 expression from a human airway epithelial cell line and it prevented P. aeruginosa-induced IL-8 expression in vitro, in the intact airway it may act as an adjuvant, boosting other immune responses to bacterial antigens. The widespread evidence of TNF-a expression and airway edema noted in the dextrantreated control mice suggests that dextran may activate additional cytokine pathways. Stimulation of the immune function of epithelial cells by dextran may have contributed to the increased clearance of the bacterial load by the dextran-treated mice.
To contemplate the therapeutic use of aerosolized dextran in humans, it is important to consider how this compound might affect the milieu in the airway lumen. The addition of such an osmotic load, which might decrease the local activity of saltsensitive defensins [5, 6] and promote bacterial survival, was apparently either negligible or negated by the beneficial effects of dextran. Similarly, P. aeruginosa, which metabolizes carbohydrate sources less desirable to other organisms, did not have any appreciable growth advantage in the presence of dextran. Importantly, studies of macrophage ingestion and PMNL killing done in the presence of dextran confirmed that the net phagocytic response to the bacterial challenge was unimpaired despite significant uptake of the compound by these cells. It remains to be established whether repeated administration of aerosolized dextran will be as well tolerated or if it results in either sensitization or tolerance by the immune system.
Exactly how dextran aerosols act to protect the murine lungs from developing P. aeruginosa pneumonia remains unclear; however, the combined effects of several factors seem likely. Complex polysaccharides appear to physically impede the relatively large bacterial ligands from accessing specific receptors, even if there is no competitive affinity for either a specific ligand or receptor. While this effect decreased bacterial induction of epithelial IL-8, other immune effectors apparently are induced to provide a means of bacterial clearance from the airways. In a recent study, dextran appeared to improve mucociliary clearance of CF sputum as monitored by a frog palate mucociliary transportability assay [14] . Together the combined immunostimulation of the epithelial cell, effect on sputum rheology, and the modest barrier function may account for the beneficial effect of dextran in preventing P. aeruginosa pneumonia in this mouse model. Innumerable complex polysaccharides with varied configurations depending on molecular weight and branching structures are available to test in such model systems. There may be more effective nontoxic carbohydrates that could be used to prevent the acquisition of airway pathogens in selected clinical settings.
